Lexeo Therapeutics, Inc. SEC filings LXEO
Lexeo Therapeutics, Inc. has 361 filings in SEC EDGAR's recent list, going back to Feb 4, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (acquisition or sale of assets, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 4, 2026 | — |
| EFFECT | Filing | Nov 26, 2025 | — |
| CORRESP | Letter to the SEC | Nov 25, 2025 | — |
| EFFECT | Filing | Jun 30, 2025 | — |
| CORRESP | Letter to the SEC | Jun 27, 2025 | — |
| CORRESP | Letter to the SEC | Jun 26, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2025 | — |
| EFFECT | Filing | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 17, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| EFFECT | Filing | Dec 3, 2024 | — |
| EFFECT | Filing | Apr 12, 2024 | — |
| CORRESP | Letter to the SEC | Apr 11, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2024 | — |
| SEC STAFF LETTER | Filing | Nov 6, 2023 | — |
| EFFECT | Filing | Nov 2, 2023 | — |
| CERT | Filing | Nov 2, 2023 | — |
| CORRESP | Letter to the SEC | Nov 1, 2023 | — |
| 8-A12B | Filing | Nov 1, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2023 | — |
| CORRESP | Letter to the SEC | Oct 31, 2023 | — |
| CORRESP | Letter to the SEC | Oct 31, 2023 | — |
| CORRESP | Letter to the SEC | Oct 5, 2023 | — |
| SEC STAFF LETTER | Filing | Sep 19, 2023 | — |
| DRSLTR | Filing | Sep 18, 2023 | — |
| DRS/A | Filing | Sep 18, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2023 | — |
| DRS/A | Filing | Aug 16, 2023 | — |
| DRSLTR | Filing | Aug 15, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2023 | — |
| DRSLTR | Filing | May 17, 2023 | — |
| DRS/A | Filing | May 17, 2023 | — |
| UPLOAD | Letter from the SEC | May 17, 2022 | — |
| DRSLTR | Filing | May 5, 2022 | — |
| DRS/A | Filing | May 5, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 3, 2022 | — |
| DRS | Filing | Feb 4, 2022 | — |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LXEO (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1907108
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.